Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York, NY, USA.
EMBO Rep. 2021 Feb 3;22(2):e48351. doi: 10.15252/embr.201948351. Epub 2021 Jan 6.
Esophageal squamous cell carcinoma (ESCC) is the most common subtype of esophageal cancer worldwide. The most commonly mutated gene in ESCC is TP53. Using a combinatorial genetic and carcinogenic approach, we generate a novel mouse model of ESCC expressing either mutant or null p53 and show that mutant p53 exhibits enhanced tumorigenic properties and displays a distinct genomic profile. Through RNA-seq analysis, we identify several endocytic recycling genes, including Rab Coupling Protein (Rab11-FIP1), which are significantly downregulated in mutant p53 tumor cells. In 3-dimensional (3D) organoid models, genetic knockdown of Rab11-FIP1 results in increased organoid size. Loss of Rab11-FIP1 increases tumor cell invasion in part through mutant p53 but also in an independent manner. Furthermore, loss of Rab11-FIP1 in human ESCC cell lines decreases E-cadherin expression and increases mesenchymal lineage-specific markers, suggesting induction of epithelial-mesenchymal transition (EMT). Rab11-FIP1 regulates EMT through direct inhibition of Zeb1, a key EMT transcriptional factor. Our novel findings reveal that Rab11-FIP1 regulates organoid formation, tumor cell invasion, and EMT.
食管鳞状细胞癌(ESCC)是全球最常见的食管癌亚型。ESCC 中最常见的突变基因是 TP53。我们采用组合遗传和致癌方法,构建了一种新型 ESCC 小鼠模型,表达突变型或缺失型 p53,并表明突变型 p53 具有增强的致瘤特性,并表现出独特的基因组特征。通过 RNA-seq 分析,我们鉴定了几个内吞回收基因,包括 Rab 衔接蛋白(Rab11-FIP1),其在突变型 p53 肿瘤细胞中显著下调。在 3 维(3D)类器官模型中,Rab11-FIP1 的基因敲低导致类器官增大。Rab11-FIP1 的缺失通过突变型 p53 增加肿瘤细胞侵袭,但也以独立方式增加。此外,人 ESCC 细胞系中 Rab11-FIP1 的缺失降低了 E-钙粘蛋白的表达并增加了间质谱系特异性标志物,提示诱导上皮-间充质转化(EMT)。Rab11-FIP1 通过直接抑制 EMT 关键转录因子 Zeb1 来调节 EMT。我们的新发现表明,Rab11-FIP1 调节类器官形成、肿瘤细胞侵袭和 EMT。
MedComm (2020). 2024-10-15
Cancer Genomics Proteomics. 2024
Cancer Discov. 2023-12-12
Exp Hematol Oncol. 2023-8-3
ASN Neuro. 2022
World J Gastrointest Oncol. 2022-7-15
J Enzyme Inhib Med Chem. 2022-12
Front Mol Biosci. 2022-6-23
N Engl J Med. 2014-12-25
Nat Rev Cancer. 2014-4-17